BioCorRx Inc (BICX)
OTHER OTC:BICX
Top Page
BioCorRx
(OTC:BICX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.39
▲(23.13% Upside)
Action:ReiteratedDate:04/03/26
The score is primarily weighed down by very weak financial performance (deep losses, negative cash flow, and negative equity). Technical signals are comparatively supportive with the stock trading above key moving averages and positive MACD, but valuation remains constrained by ongoing unprofitability. The recent reorganization is a modest positive for structure/control, partially offset by dilution considerations.
Positive Factors
Revenue rebound (2025)
A sharp revenue rebound in 2025 demonstrates the company can restore top-line scale after a trough. Sustained revenue recovery supports investments in operations and clinical programs and is a necessary precursor to durable margin recovery and improved operating leverage over the next 2–6 months.
Negative Factors
Persistent unprofitability
Multi-year unprofitability erodes capital and raises the bar for sustainable operations. Continued negative operating results imply underlying economics have not stabilized, making achievement of consistent positive margins unlikely without structural changes or sustained revenue strength.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound (2025)
A sharp revenue rebound in 2025 demonstrates the company can restore top-line scale after a trough. Sustained revenue recovery supports investments in operations and clinical programs and is a necessary precursor to durable margin recovery and improved operating leverage over the next 2–6 months.
Read all positive factors
BioCorRx (BICX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.56M
Dividend YieldN/A
Average Volume (3M)824.00
Price to Earnings (P/E)―
Beta (1Y)0.43
Revenue Growth3464.86%
EPS Growth38.01%
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.07
Shares Outstanding26,402,874
10 Day Avg. Volume1,315
30 Day Avg. Volume824
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.48
Price to Sales (P/S)6.75
P/FCF Ratio-2.34
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue11.80
Enterprise Value/Gross Profit13.37
Enterprise Value/Ebitda-3.86
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$971.85K
BioCorRx Business Overview & Revenue Model
Company Description
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatm...
How the Company Makes Money
null...
BioCorRx Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
6
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 797.24K | 7.67K | 89.16K | 213.84K | 48.27K |
| Gross Profit | 775.44K | 6.00K | 53.17K | 198.56K | 42.39K |
| EBITDA | -2.56M | -3.59M | -2.68M | -3.15M | -4.48M |
| Net Income | -3.44M | -5.11M | -3.77M | -4.37M | -5.80M |
Balance Sheet | |||||
| Total Assets | 2.15M | 385.94K | 388.89K | 766.59K | 819.98K |
| Cash, Cash Equivalents and Short-Term Investments | 139.36K | 88.03K | 65.22K | 68.61K | 85.84K |
| Total Debt | 2.13M | 2.81M | 1.81M | 1.68M | 1.77M |
| Total Liabilities | 13.67M | 12.74M | 10.34M | 8.97M | 7.78M |
| Stockholders Equity | -11.22M | -12.12M | -9.82M | -8.08M | -6.84M |
Cash Flow | |||||
| Free Cash Flow | -2.30M | -1.10M | -1.85M | -2.04M | -3.59M |
| Operating Cash Flow | -2.30M | -1.10M | -1.85M | -2.04M | -3.54M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -50.00K |
| Financing Cash Flow | 2.35M | 1.12M | 1.85M | 2.02M | 3.08M |
BioCorRx Technical Analysis
Positive
0.32
Price Trends
0.35
Positive
0.35
Positive
0.37
Positive
Market Momentum
0.01
Positive
59.29
Neutral
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BICX, the sentiment is Positive. The current price of 0.32 is below the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.35, and below the 200-day MA of 0.37, indicating a bullish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 59.29 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BICX.
BioCorRx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $307.39M | -54.27 | 759.71% | ― | 21.67% | 16.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $536.16M | -2.24 | -335.93% | ― | ― | -21.62% | |
47 Neutral | $10.56M | -1.56 | 41.44% | ― | 3464.86% | 38.01% | |
44 Neutral | $8.78M | -8.99 | -8.75% | ― | 17.84% | -156.13% | |
44 Neutral | $16.50M | -0.11 | ― | ― | -22.38% | 56.66% | |
43 Neutral | $29.80M | -13.22 | 15.27% | 11.14% | -0.29% | 94.56% |
* Healthcare Sector Average
BICX
BioCorRx
0.40
-0.09
-18.37%
AMS
American Shared Hospital Services
1.33
-1.45
-52.16%
CCM
Concord Medical Services
3.80
-0.30
-7.32%
CCEL
Cryo-Cell International
3.70
-1.67
-31.09%
TOI
Oncology Institute
3.11
1.42
84.02%
CMPS
COMPASS Pathways
5.58
2.88
106.67%
BioCorRx Corporate Events
Business Operations and StrategyPrivate Placements and Financing
BioCorRx Reorganizes Subsidiary Through Equity Exchange Deal
Positive
Apr 2, 2026
On March 26, 2026, BioCorRx Inc. entered into a stock exchange agreement with three director-shareholders under which they transferred a total of 1,215 shares of BioCorRx Pharmaceuticals Inc., representing about 12.15% of the subsidiary’s ou...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.